Arcutis Biotherapeutics Says ZORYVE Foam 0.3% Linked To Adverse Reactions Including Headache, Nausea, And Diarrhea, With Flammability Risk And Contraindications For Liver-Impaired Patients Highlighted In Safety Profile Under FDA Review

BenzingaMay 7 11:32 ET

Arcutis Biotherapeutics: Zoryve Foam Treatment Resulted in Major Improvements

TipRanksMay 7 11:26 ET

Arcutis Biotherapeutics Reports Positive Phase 3 Study Results for Investigational ZORYVE Foam 0.3% in Treating Scalp and Body Psoriasis

Quiver QuantitativeMay 7 11:20 ET

Arcutis Announces Publication of Positive Data From ARRECTOR Trial Evaluating ZORYVE (Roflumilast) Foam 0.3% in Individuals With Psoriasis in Journal of American Medical Association Dermatology

GlobeNewswireMay 7 11:18 ET

Analysts Are Bullish on These Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Praxis Precision Medicines (PRAX)

TipRanksMay 7 04:30 ET · Ratings

Earnings Call Summary | Arcutis Biotherapeutics(ARQT.US) Q1 2025 Earnings Conference

moomoo AIMay 6 23:18 ET · Conference Call